Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?

Introduction One of the most often stated tenets haemophilia care is that prophylaxis converts a person from severe to moderate phenotype. In this review, we argue not an accurate assumption and people on predominantly have factor VIII/IX levels in mild range. Moderate People with haemophilia, who are treating on-demand regimens, experience joint bleeds develop significant arthropathy. This especially true for baseline level 1‒3 IU/dl, as first reported 55 years ago, confirmed more recent studies. Evidence emerging suggesting using better musculoskeletal outcomes than treated episodically. Trough The debate around optimum trough whilst ongoing. It appropriate extrapolate information about recommendations target because these different situations. Studies support higher previously used, but spite this, aim achieving zero remains elusive both replacement non-replacement therapies. Conclusions We recommend those 1–3 should be offered based same criteria haemophilia. maintained above 3 IU/dl or if does control breakthrough bleeding tailored advice line recently published guidelines World Federation Haemophilia UK Centre Doctors’ Organisation.